Improved enzymatic isolation of fibroblasts for the creation of autologous skin substitutes.
The number of medical applications using autologous fibroblasts is increasing rapidly. We investigated thoroughly the procedure to isolate cells from skin using the enzymatic tissue dissociation procedure. Tissue digestion efficiency, cell viability, and yield were investigated in relation to size of tissue fragments, digestion volume to tissue ratio, digestion time, and importance of other protease activities present in Clostridium histolyticum collagenase (CHC) (neutral protease, clostripain, and trypsin). The results showed that digestion was optimal with small tissue fragments (2-3 mm3) and with volumes tissue ratios > or =2 ml/g tissue. For incubations < or =10 h, the digestion efficiency and cell isolation yields were significantly improved by increasing the collagenase, neutral protease, or clostripain activity, whereas trypsin activity had no effects. However, a too high proteolytic activity of one of the proteases present in CHC digestion solution or long exposure times interfered with cell viability and cell culture yields. The optimal range of CHC proteases activities per milliliter digestion solutions was determined for digestions < or =10 h (collagenase 2700-3900 Mandl U/ml, neutral protease 5100-10,000 caseinase U/ml, and clostripain 35-48 BAEE U/ml) and for longer digestions (>14 h) (collagenase 1350- 3000 U/ml, neutral protease 2550-7700 U/ml, and clostripain 18-36 U/ml). Using these conditions, a maximum fibroblast expansion was achieved when isolated cells were seeded at 1 x 10(4) cells/cm2. These results did not only allow selection of optimal CHC batches able to digest dermal tissue with an high cell viability but also significantly increased the fibroblast yields, enabling us to produce autologous dermal tissue in a clinically acceptable time frame of 3 wk.
Wang
Hongjun
H
Institute of Biomedical Technology, Twente University, 7500 AE Enschede, The Netherlands.
Van Blitterswijk
Clemens A
CA
Bertrand-De Haas
Marion
M
Schuurman
Arnold H
AH
Lamme
Evert N
EN
D005347:Fibroblasts / Q000166:cytology* / Q000378:metabolism; D006801:Humans; D003012:Microbial Collagenase / Q000378:metabolism; D012867:Skin / Q000166:cytology; D017768:Skin, Artificial; D023822:Tissue Engineering / Q000379:methods; D014182:Transplantation, Autologous
D003012:Microbial Collagenase
Transplant Proc. 1999 Feb-Mar;31(1-2):1165-6
10083520
Am J Physiol. 1981 May;240(5):C234-8
6263099
Pharmacol Toxicol. 1995 Jan;76(1):68-71
7753761
Mol Biol Cell. 2002 Dec;13(12):4279-95
12475952
Transplant Proc. 1997 Jun;29(4):1942-4
9193463
J Protein Chem. 1992 Feb;11(1):99-107
1325155
Horm Metab Res Suppl. 1990;25:20-6
1965179
Tissue Eng. 2003 Oct;9(5):909-17
14633375
Exp Cell Res. 1983 Nov;149(1):227-36
6315459
Wound Repair Regen. 2002 May-Jun;10(3):152-60
12100376
Cell Transplant. 2001;10(8):709-16
11814113
Nat Cell Biol. 2001 Sep;3(9):778-84
11533656
J Biol Chem. 1968 Sep 25;243(18):4683-92
4971659
Cell Transplant. 1996 Sep-Oct;5(5):543-51
8889213
Biochemistry. 1984 Jun 19;23(13):3077-85
6087887
Biochim Biophys Acta. 1969 Apr 22;178(2):397-400
4306267
Acta Derm Venereol. 1978;58(3):197-202
78632
Am J Surg. 2002 Apr;183(4):445-56
11975935
Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10114-8
1438199
Eur J Biochem. 1983 Dec 1;137(1-2):311-8
6317390
N Engl J Med. 2001 Jun 7;344(23):1735-42
11396439
J Invest Dermatol. 1998 Dec;111(6):989-95
9856806
In Vitro Cell Dev Biol Anim. 1995 Jun;31(6):447-55
8589888
Cell Transplant. 1998 Jul-Aug;7(4):365-72
9710305
Cell Transplant. 1996 Jul-Aug;5(4):437-52
8800512
J Biomed Mater Res. 1999 Dec 5;47(3):292-300
10487879
Biomaterials. 2002 Feb;23(4):1169-85
11791921
Biochem Int. 1991 Jun;24(3):397-404
1663343
J Bone Miner Res. 1991 Mar;6(3):217-26
1852087
Genes Dev. 2001 Feb 15;15(4):398-403
11230148
Diabetes. 1995 Feb;44(2):227-33
7859945
Diabetologia. 1992 Aug;35(8):735-42
1324862
Hum Gene Ther. 1994 Aug;5(8):997-1017
7948149
J Bone Miner Res. 1987 Dec;2(6):505-16
2844066
Bull Exp Biol Med. 2000 Aug;130(8):786-9
11177245
Cell Transplant. 1995 May-Jun;4(3):281-9
7640867
Science. 1968 Oct 18;162(3851):374-5
5677534
Biochemistry. 1984 Jun 19;23(13):3085-91
6087888
Toxicon. 2001 Nov;39(11):1769-80
11595639
Diabetes. 1997 Jul;46(7):1120-3
9200645
Burns. 1992;18 Suppl 2:S19-22
1418518
Biochemistry. 1987 Feb 10;26(3):681-7
3032235
Transplantation. 1999 Sep 27;68(6):868-79
10515389
Dermatol Surg. 1998 May;24(5):510-2
9598003
Arch Dermatol Res. 2002 May;294(3):135-42
12029501
Adv Drug Deliv Rev. 1998 Aug 3;33(1-2):165-182
10837658
J Pathol. 2000 Apr;190(5):595-603
10727986
J Hematother Stem Cell Res. 2001 Jun;10(3):341-6
11454309
J Biomed Mater Res. 1994 May;28(5):545-52
8027095
Biochim Biophys Acta. 1965 Sep 20;105(3):562-74
4285899
Arch Facial Plast Surg. 1999 Jul-Sep;1(3):165-70
10937098
EMBO J. 2003 Aug 1;22(15):4003-13
12881434
Cancer Res. 1984 Jun;44(6):2291-6
6722770
In Vitro Cell Dev Biol Anim. 2001 Jul-Aug;37(7):408-13
11573814
Transplant Proc. 1997 Jun;29(4):1939-41
9193462
Transplant Proc. 1994 Apr;26(2):641-2
8171590